ABUS vs CNC · P/E 5.4, rev $6.2M vs P/E 8.4, rev $163.07B
Arbutus Biopharma Corp (ABUS) versus Centene Corp (CNC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Centene Corp (CNC) is a healthcare plans company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CNC revenue for 2024-12-31 was $163.07B. Net income was $3.29B. Revenue was up 5.9% from 2023-12-31 to 2024-12-31. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CNC currently screens at market cap $28.19B and trailing P/E 8.4.
Not investment advice. Open the ABUS and CNC stock pages for the full models.
Not investment advice.